Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Kaempferol and Oxaliplatin

supplement:

Kaempferol

Research Papers that Mention the Interaction

The present study also elucidated the mechanism by which LUT potentiated the sensitivity of SGC-7901 cells to OXA through the Cyt c/caspase pathway.
The results of this study show that the combination of LUT and OXA inhibited SGC-7901 cell proliferation and induced apoptosis by altering cell-cycle proportions.
BioMed research international  •  2020  |  View Paper
Moreover, luteolin treatment was found to reduce oxaliplatin-treated p53-null cell viability and colony counts further, thereby demonstrating an additional effect of luteolin in the killing of human colorectal tumor HCT116 cells not expressing functional p53 protein.
This study aimed to examine if luteolin , an Nrf2 activator, hinders chemotherapeutic activity of oxaliplatin , a potent anticancer agent for colorectal cancer, in HCT116 cells.
Nutrients  •  2019  |  View Paper
Moreover, cell viability and cell apoptosis assays showed that luteolin increased oxaliplatin uptake and intracellular accumulation through OCTN2.
This induction was attenuated by PPAR&ggr; antagonist GW9662 as well as by PPAR&ggr; knockdown, suggesting that the induction by luteolin is dependent on PPAR&ggr;. In uptake studies, luteolin increased the binding affinity of OCTN2 toward oxaliplatin and enhanced intracellular concentration of oxaliplatin.
Thus, our study showed that luteolin increased the sensitivity of colorectal cancer SW480 cells to oxaliplatin , likely through the PPAR&ggr;/OCTN2 pathway.
Anti-cancer drugs  •  2014  |  View Paper
At physiological concentrations, luteolin significantly sensitized A549 cells to the anticancer drugs oxaliplatin , bleomycin, and doxorubicin.
Free radical biology & medicine  •  2011  |  View Paper